Core--Formulations

核心--配方

• 批准号: 7132119
• 负责人: Joe A. McDonough
• 金额: $ 14.14万
• 依托单位: RHODE ISLAND HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-07-01 至 2010-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7132119
• 关键词: RNA interference; antiviral agents; biomedical facility; biotechnology; chemical synthesis; cooperative study; drug delivery systems; mucosa; nanotechnology; rectum /anus; small interfering RNA; technology /technique development; topical drug application; vagina

The formulations core will be led by Southwest Research Institute, a commercial entity with expertise in formulating drug for mucosal delivery. The singular purpose of this Core will be to develop a nanocapsular formulation of short interfering RNA (siRNA) that will be appropriate for mucosal delivery. To accomplish this goal, various nanocapsular formulations will be synthesized and tested for their ability to incorporate and deliver siRNA to the cellular cytoplasm; Initial experiments will use a siRNA molecule conjugated to a fluorophore, this allowing rapid microscopic evaluation of the efficiency of cellular entry. Once an optimum formulation is identified, this Core will produce formulations of siRNA targeting macaque CCR5 and enhanced green fluorescent protein in year 1. These products will be supplied to Projects by Ramratnam and Lambert for in vitro and in vivo evaluations of gene silencing potency and toxicity. These evaluations will allow us to decide upon an optimum formulation conditions that will be used to formulate siRNAs identified by Projects by Herold and Lambert in future years of the grant.

配方核心将由商业实体西南研究所领导 具有为粘膜递送的药物配制的专业知识。这个核心的单一目的将是 开发短干扰RNA（siRNA）的纳米胶囊配方，这将适合 粘膜输送。为了实现这一目标，将合成各种纳米胶囊配方 并测试了它们将siRNA掺入细胞细胞质的能力；最初的 实验将使用连接到荧光团的siRNA分子，这允许快速微观 评估细胞进入效率。一旦确定了最佳公式，该核心将 产生靶向猕猴CCR5和增强的绿色荧光蛋白的siRNA制剂 1年级。这些产品将由Ramratnam和Lambert提供给项目，以进行体外和体内评估 基因沉默的效力和毒性。这些评估将使我们能够决定最佳 将来，将来，将来，将来，将来，将来，将来，将来，将来，将来，将来，将来，将来，将来，将来，将来，将来，将来，将来，赫罗德（Herold）和兰伯特（Lambert）确定了sirnas 赠款年。